Sunshine Biopharma market cap SBFM
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $533.1K
- Highest close in our data
- $43M
- Apr 2022
Sunshine Biopharma is worth $533.1K at the close on Nov 2, 2026, at $2.75 a share.
That is down 93% over the last year and down 95% over five years.
Its highest close in our data was $43M in Apr 2022.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $533.1K | $533.1K | $6.5M | −91% |
| 2025 | $6.2M | $3.4M | $9.5M | +1% |
| 2024 | $6.1M | $835.4K | $14.3M | −12% |
| 2023 | $7M | $6.1M | $25.7M | −52% |
| 2022 | $14.5M | $4.5M | $43M | +92% |
| 2021 | $7.5M | $1.4M | $24.4M | +477% |
| 2020 | $1.3M | $13K | $1.8M | +1907% |
| 2019 | $65K | $23.3K | $408.2K | −83% |
| 2018 | $387.8K | $204.1K | $3.2M | −86% |
| 2017 | $2.7M | $411.8K | $3.6M | +298% |
| 2016 | $686.4K | $251K | $1.2M | +54% |
| 2015 | $447K | $99.7K | $942.9K | −7% |
| 2014 | $482.4K | $396.2K | $3.1M | −80% |
| 2013 | $2.4M | $2.1M | $5.6M | −54% |
| 2012 | $5.3M | $1.6M | $7.1M | +209% |
| 2011 | $1.7M | $1.5M | $10M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Sunshine Biopharma's size, closest first, today.
| Company | Market cap |
|---|---|
| SBFMSunshine Biopharma | $533.1K |
| VBIOValion Bio | $471.2K |
| LABTLakewood-Amedex Biotherapeutics | $438.4K |
| DCOYDecoy Therapeutics | $678.1K |
| NXTSNexentis Technologies | $772.3K |
| LNAILunai Bioworks | $830.7K |
| JAGXJaguar Health | $304.6K |
| ARTLArtelo Biosciences | $1.1M |
| GOVXGeoVax Labs | $1.2M |
| MTNBMatinas BioPharma | $1.3M |
| KAPAKairos Pharma, LTD. | $1.6M |
| Peer median | $801.5K |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Sunshine Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.